Evidence map›Paper›PMID 41502651›Full record

ReviewACS omega2025

Vanillin Derivatives in Drug Design: Structure-Activity Relationship (SAR) Hotspots and Synthetic Pathways for Enhanced Pharmacological Activity.

Mustapha Suleiman, Murugesan Sankaranarayanan, Kumitaa Theva Das, Syazwani Itri Amran, Vladimir Berezin, Bogoyavlenskiy Andrey, Joazaizulfazli Jamalis

Abstract readReview
In one paragraph

Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mustapha SuleimanDepartment of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor Malaysia.
Murugesan SankaranarayananMedicinal Chemistry Research Laboratory, Birla Institute of Technology & Science Pilani (BITS Pilani), Pilani Campus, Pilani 333031, Rajasthan India.ORCID https://orcid.org/0000-0002-3680-1577
Kumitaa Theva DasInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Gelugor 11800, Penang Malaysia.
Syazwani Itri AmranDepartment of Biosciences, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor Malaysia.
Vladimir BerezinResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Bogoyavlenskiy AndreyResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.ORCID https://orcid.org/0000-0001-9579-2298
Joazaizulfazli JamalisDepartment of Chemistry, Faculty of Science, Universiti Teknologi Malaysia, Johor Bahru 81310, Johor Malaysia.ORCID https://orcid.org/0000-0002-1756-7244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug discovery often uses privileged molecular scaffolds, such as vanillin, which are naturally found in plants for drug design and synthesis. Incorporating vanillin into standard chemical structures and synthesizing novel derivatives with active scaffolds are vital for developing effective therapeutic candidates. The aromatic ring of vanillin contains functional groups such as aldehyde, hydroxyl, and ether, which facilitate its modification and the generation of various resultant derivatives with promising biological activities. Consequently, numerous strategies have been developed and incorporated into synthetic pathways to produce biologically potent vanillin derivatives. Vanillin-based compounds have demonstrated effectiveness against a wide range of emerging infectious diseases. This review focuses on the key structure-activity relationship hotspots within vanillin derivatives that influence their biological activity. By examining the synthetic pathways developed over the past decade (2014-2025), we highlight how targeted modifications at specific SAR hotspots can enhance the therapeutic potential of these compounds, such as antitubercular, antioxidant, antimalarial, anticancer, and anti-inflammatory properties.

Identifiers

PMID41502651
PMCPMC12771428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.